Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer.

Yoshii H, Ito K, Asano T, Horiguchi A, Hayakawa M, Asano T.

Oncol Rep. 2013 Sep;30(3):1073-80. doi: 10.3892/or.2013.2577. Epub 2013 Jul 1.

PMID:
23817592
2.

Dual role of TGFBR3 in bladder cancer.

Liu XL, Xiao K, Xue B, Yang D, Lei Z, Shan Y, Zhang HT.

Oncol Rep. 2013 Sep;30(3):1301-8. doi: 10.3892/or.2013.2599. Epub 2013 Jul 8.

PMID:
23835618
3.

Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.

Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ahmed Ael-F, Fujisawa M.

Urol Oncol. 2011 Sep-Oct;29(5):495-501. doi: 10.1016/j.urolonc.2009.08.002. Epub 2009 Nov 13.

PMID:
19914103
4.

High FOXM1 expression was associated with bladder carcinogenesis.

Liu D, Zhang Z, Kong CZ.

Tumour Biol. 2013 Apr;34(2):1131-8. doi: 10.1007/s13277-013-0654-x. Epub 2013 Jan 17.

PMID:
23325617
5.

Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.

Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.

Eur Urol. 2005 Jul;48(1):53-9; discussion 59. Epub 2005 Apr 7.

PMID:
15967252
6.

Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.

Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES.

Anticancer Res. 2016 Feb;36(2):495-501.

PMID:
26851002
7.

The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.

Nonomura N, Nakai Y, Nakayama M, Inoue H, Nishimura K, Hatanaka E, Arima R, Kishimoto T, Miki T, Kuroda H, Okuyama A.

Int J Clin Oncol. 2006 Aug;11(4):297-302.

PMID:
16937303
8.

A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma.

Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V.

BJU Int. 2005 Mar;95(4):655-9.

9.

High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

Zhang Z, Zhang G, Kong C.

Urol Oncol. 2013 Oct;31(7):1222-30. doi: 10.1016/j.urolonc.2011.11.028. Epub 2011 Dec 20.

PMID:
22192978
10.

High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

Li W, Liu M, Feng Y, Huang YF, Xu YF, Che JP, Wang GC, Zheng JH.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2430-40. eCollection 2013.

11.

Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.

Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG.

J Urol. 2006 Aug;176(2):493-8; discussion 498-9.

PMID:
16813876
12.

SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.

Keck B, Wach S, Goebell PJ, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A.

Ann Surg Oncol. 2013 Oct;20(11):3669-74. doi: 10.1245/s10434-013-3075-6. Epub 2013 Jun 27.

PMID:
23807662
13.

Management of high-risk non-muscle invasive bladder cancer.

Brausi M, Olaru V.

Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Review.

PMID:
23288212
14.

Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.

Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF.

Urology. 2007 Sep;70(3):482-6.

PMID:
17905101
15.

Histological growth pattern of and alpha-actinin-4 expression in thyroid cancer.

Tanaka N, Yamashita T, Yamamoto S, Matsunobu T, Tsuda H, Honda K, Yamada T, Tamai S, Shiotani A.

Anticancer Res. 2014 Jun;34(6):3157-63.

PMID:
24922688
16.

Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.

Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP.

Clin Cancer Res. 2001 Sep;7(9):2840-53.

17.

The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.

Solsona E, Iborra I, Rubio J, Casanova J, Almenar S.

BJU Int. 2004 Dec;94(9):1258-62.

18.

Expression of aquaporin 1 in bladder uroepithelial cell carcinoma and its relevance to recurrence.

Liu J, Zhang WY, Ding DG.

Asian Pac J Cancer Prev. 2015;16(9):3973-6.

19.

Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.

Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M.

Int J Cancer. 2006 Sep 15;119(6):1396-402.

20.

Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.

Solsona E, Iborra I, Ricos JV, Monros JL, Rubio J, Almenar S.

J Urol. 2002 May;167(5):2007-11.

PMID:
11956428
Items per page

Supplemental Content

Write to the Help Desk